All In Biotech

Drug Trial Radar · NCT00981058

First-line Treatment of Participants With Stage IV Squamous Non-Small Cell Lung Cancer With Necitumumab and Gemcitabine-Cisplatin

A Randomized, Multicenter, Open-Label Phase 3 Study of Gemcitabine-Cisplatin Chemotherapy Plus Necitumumab (IMC-11F8) Versus Gemcitabine-Cisplatin Chemotherapy Alone in the First-Line Treatment of Patients With Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC)

Last checked: Nov 20, 2026Latest source record: Jun 18, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,093 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,093

Actual

Start

Jan 7, 2010

Primary completion

Jun 17, 2013

Study completion May 30, 2024

Sponsor

Lead sponsor
Eli Lilly and CompanyEli Lilly (LLY)
Sponsor type
Industry
Collaborators
Parexel; PPD Development, LP; Medidata Solutions; Laboratory Corporation of America; University of Colorado, Denver; Thermo Fisher Scientific FS; ICON Clinical Research; Pacific Biomarkers; Sysmex Inostics GmbH; Intertek
First posted
Sep 22, 2009

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The research study is testing the investigational drug necitumumab (IMC-11F8) in the treatment of advanced non-small cell lung cancer. The aim of this study is to determine if necitumumab, given together with a standard chemotherapy combination consisting of cisplatin and gemcitabine will be more effective in improving participant disease than the standard chemotherapy combination alone.

Conditions

  • Non Small Cell Lung Cancer

Interventions

  • NecitumumabBiological

    Administered intravenously. Continues until progressive disease, toxicity, noncompliance, or withdrawal.

  • GemcitabineDrug

    Administered intravenously. Continues for a maximum of six cycles.

  • CisplatinDrug

    Administered intravenously. Continues for a maximum of six cycles.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall Survival Time (OS)Time frame: Randomization to Death from Any Cause (Up to 31 Months)

Locations

182 sites in 26 countries. Site status is shown where the registry gives one.

  • ImClone Investigational Site

    Chandler, Arizona

  • ImClone Investigational Site

    Fayetteville, Arkansas

  • ImClone Investigational Site

    Sacramento, California

  • ImClone Investigational Site

    Galesburg, Illinois

  • ImClone Investigational Site

    Goshen, Indiana

  • ImClone Investigational Site

    Wichita, Kansas

  • ImClone Investigational Site

    Hazard, Kentucky

  • ImClone Investigational Site

    Baltimore, Maryland

  • ImClone Investigational Site

    Jefferson City, Missouri

  • ImClone Investigational Site

    Lincoln, Nebraska

  • ImClone Investigational Site

    New York, New York

  • ImClone Investigational Site

    Akron, Ohio

  • ImClone Investigational Site

    Camp Hill, Pennsylvania

  • ImClone Investigational Site

    Memphis, Tennessee

  • ImClone Investigational Site

    Fairfax, Virginia

  • ImClone Investigational Site

    Garran, New South Wales, Australia

  • ImClone Investigational Site

    Westmead, New South Wales, Australia

  • ImClone Investigational Site

    Wollongong, New South Wales, Australia

  • ImClone Investigational Site

    East Bentleigh, Victoria, Australia

  • ImClone Investigational Site

    Geelong, Victoria, Australia

  • ImClone Investigational Site

    Linz, Austria

  • ImClone Investigational Site

    Vienna, Austria

  • ImClone Investigational Site

    Vienna, Austria

  • ImClone Investigational Site

    Duffel, Belgium

  • ImClone Investigational Site

    Liège, Belgium

  • ImClone Investigational Site

    Namur, Belgium

  • ImClone Investigational Site

    Barretos, Brazil

  • ImClone Investigational Site

    Brasilia, Distrito Federal, Brazil

  • ImClone Investigational Site

    Goiânia, Brazil

  • ImClone Investigational Site

    Ijuí, Brazil

  • ImClone Investigational Site

    Itajaí, Brazil

  • ImClone Investigational Site

    Lajeado, Brazil

  • ImClone Investigational Site

    Porto Alegre/RS, Brazil

  • ImClone Investigational Site

    Salvador, Brazil

  • ImClone Investigational Site

    Santo André, Brazil

  • ImClone Investigational Site

    São Paulo, Brazil

  • ImClone Investigational Site

    São Paulo - SP, Brazil

  • ImClone Investigational Site

    Saint John, New Brunswick, Canada

  • ImClone Investigational Site

    Brampton, Ontario, Canada

  • ImClone Investigational Site

    Saskatoon, Saskatchewan, Canada

Showing 40 of 182 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.